Download AAMCN Pre Conference Learning Objectives At the conclusion of

AAMCN Pre Conference Learning Objectives
At the conclusion of the Pre Conference sessions, you should be able to:
 Discuss the need for intensive case management of the Medicaid behavioral health population
 Describe AmeriGroup’s Rising Star Program
 Recognize methods that could be used in other populations
 Identify issues associated with early PD diagnosis and management through end of life care
 Describe the role of the managed care nurses, including case managers, in working with the PD
patient through the life continuum
 List and implement nursing strategies in the care of PD patients and their caregivers
 Recognize the challenges of PD pharmacologic therapy in managed care.
 Define the issue of providing nursing/case management services across state lines
 Identify existing barriers to the Nurse Licensure Compact (NLC)
 Describe nationwide efforts and initiative support state by state adoption of the NLC
 Describe how and why the state of OH determined the need for a UM Consortium
 Discuss the role of the managed care nurse in a UM Consortium
 Discuss the impact on patient care of a UM Consortium
 Define social media
 Identity the role a managed care nurse can play in social media
 Recognize the potential impact of social media on patient outcomes
 Use social media websites such as www.aamcn.org
Fall Forum Learning Objectives
Depending on what track session you attend, at the end of the Forum, you should be able to:





Explain the mechanics of Medicare’s Value-Based Purchasing and Shared Savings Programs,
including the risk/reward tradeoffs in the various models and the types of health care institutions
most likely to be successful in them.
Describe the similarities and differences between the approaches taken by five groups of payers:
Medicare, Medicaid, commercial insurers, employers, and patients.
Identify and provide a rationale for treating patients with clinically isolated syndrome who are likely
to progress to clinically definite MS (CDMS); and, achieve reduction of EDSS that accompanies
early initiation of therapy;
Understand how the likely approval of new MS therapies—including both oral and injected
agents—may change the risk-to-benefit analyses and influence long-term treatment decisions for
MS treatment regimens implemented in the managed care setting;
Analyze and project the clinical risks and benefits of emerging agents under evaluation for MS,
and how the safety profiles of new agents compares to established platforms with documented
long-term safety and LTFU studies showing EDSS stabilization and reduction in relapse rates;






































Understand the barriers to stronger hospital-physician relationships
Understand key components necessary for improved hospital-physician relationships
Provide proven strategies and practical methods that can improve hospital -physician
relationships. Analyze clinical data evaluating the safety and efficacy of immunotherapies in the treatment of
metastatic melanoma
Review agents recently approved for the treatment of metastatic melanoma
Discuss mechanisms of immune tolerance and the rationale for using immunotherapy to treat
patients with metastatic melanoma
Incorporate strategies for anticipating, recognizing, and treating immune-related adverse events
associated with immunotherapies for metastatic melanoma
Review the changes in the AJCC staging system
Detail the criteria for determining progression to castrate-resistant prostate cancer (CRPC)
Discuss the efficacy, safety, and anticipated outcomes for recently approved agents in the
treatment of CRPC
Define the criteria by which patients with CRPC should be considered for either immunotherapybased treatment or chemotherapy
Identify strategies for managing side effects and maintaining quality of life in patients with CRPC
Review NCCN and ASCO guidelines for the treatment of CRPC
Identify comorbidities and risk factors associated with OAB
Identify appropriate screening tools for discovering patients with OAB symptoms
Discuss diagnosis methods to find the cause for the symptoms
Discuss treatments plans, including behavioral/lifestyle changes and medication
Identify key drivers of medical spend and areas of opportunity within general surgery and certain
diagnostic procedures
Learn how value based benefit designs can be used to lower medical costs
Understand how to design a surgical value based benefit program
Learn how engagement at precertification drives better decisions around surgical procedures
Identify resources and opportunities to reduce medical spending within your organization.
Discuss the efficacy and safety of targeted therapies currently used in the treatment advanced
RCC
Develop individualized treatment plans incorporating biologically targeted therapies in treatment
plans for patients with RCC to improve survival rates
Review the NCCN and ASCO treatment guidelines for advanced RCC
Analyze therapies currently undergoing late stage clinical trials and how they might affect the
future of advanced RCC treatment
Identify and manage adverse events associated with RCC therapies
Measure efficacy of PCMH implementation through well-being improvement
Correlate cost productivity and work withdrawal to well-being
Address health risks before they become conditions as a significant sources savings
Review risk factors, symptoms, clinical and functional classifications and the importance of early
diagnosis of PAH
Recognize that appropriate clinical classification diagnosis of PAH is imperative to apply treatment
algorithms accordingly and determine the best combination treatment strategy
Understand the current prevalence and economic burden of PAH and how misdiagnosis of the
patient’s classification can affect both the patient’s risk and healthcare costs
Analyze the current and prospective pharmacologic and lifestyle treatment options
Identify the role of the Medical Director and Nurse Case Manager in managing a PAH population
Describe what an ACO is
Identify who should consider participating in this type of delivery system
Discuss what technology is available to support care management efforts of an ACO































Describe the current algorithm and economical impact of hyperthyroidism
Discuss the impact of an adjustment in the algorithm could benefit the healthcare system
Recognize the ‘silent’ HIV epidemic and its underestimated need
Describe recent updates on protocols and guidelines for HIV/AIDS treatment, prevention and
screening services
Understand the disease management success when using ART and its potential long-term savings
Identify strategies for ensuring ART coverage for HIV/AIDS patients, particularly with lacking state
funds for ADAP programs
Review the economic and societal impact of HIV/AIDS and the importance of addressing internal
quality assurance
Understand the importance of early diagnosis and aggressive treatment in the management of RA
Review the diagnosis criteria for RA per the American College of Rheumatology guidelines
Analyze the clinical efficacy and safety data for the current and emerging RA therapies
Discuss possible strategies to decrease or avoid a patient’s risk for RA-associated comorbidities
Recognize the value of patient education to improve quality of care, optimize disease outcomes,
and increase patient satisfaction
Explore new models of care that promote a coordinated approach to healthcare, dedicated to
genuine improvement in quality and outcomes while better managing costs
Discuss how technology can be used to enable the level of collaboration necessary for care
coordination
Discuss case-study information about the tactics SCCIPA has adopted to being achieving higher
levels of care coordination
Review specific areas and opportunities where participants might begin to recast the traditional
roles of stakeholders in their own organizations in order to achieve long-term goals.
Compare the efficacy & safety of GLP-1 agonists, DPP-4 inhibitors, & insulin analogues in the
treatment of type 2 Diabetes
Review the morbidity & cost burdens associated with inadequate treatment and management of
type 2 diabetes
Discuss the Type 2 diabetes treatment guidelines and goals from the American Diabetes
Association
Identify the pharmacological properties and clinical data on new and emerging type 2 diabetes
therapies
Analyze the difficulties and strategies for managing patients with multiple cardiovascular risk
factors
Describe the risk factors most highly associated with non-healing, delayed healing or improper
healing in patients experiencing fractures
Discuss the trade-offs in treatment options that balance likelihood of healing, time to heal and cost
effectiveness
Analyze how to use current evidence and effectiveness data to manage costs associated with
various treatment options for patients experiencing fractures
Discuss the future of patients who have poor outcomes in conjunction with the costs associated
with continued care
Examine the current trends in physician-hospital alignment and explore various alignment models
Understand the typical process that a practice/hospital goes through to align
Define fair market value and discuss key factors of the FMV process
Discuss pharmacologic treatment options available for patients with major depressive disorder
Review diagnosis strategies from the Diagnostic and Statistical Manual of Mental Disorders
Discuss strategies for initial treatment of MDD and for treatment after therapeutic failures as
recommended by recently updated APA guidelines
































Identify follow-up tools and communication strategies to improve management of major depressive
disorder
Analyze the economic burden that major depressive disorder has on the healthcare system
Discuss current challenges in the diagnosis of hyperthyroidism
Identify tools now available for better recognition and diagnosis of hyperthyroidism
Describe how the new tools available affect the time to diagnosis and reduced morbidity
Understand the risks for CINV and its prevalence across the cancer treatment spectrum
Identify the properties and optimal use of current agents available for the prevention of CINV
Compare the recommendations for managing CINV from updated clinical practice guidelines of
NCCN and ASCO
Describe treatment options for a patient at various risk levels for developing CINV and patients
experiencing CINV
Realize the potential issues surrounding non-compliance and the risks/consequences of untreated
CINV
Summarize current, new and emerging treatment options for Multiple Myeloma (MM)
Assess the evidence for the use of novel agents in the first-line setting
Discuss current therapeutic options for patients with relapsed/refractory MM
Outline factors to be considered in diagnosis, staging and risk assessment for MM and explain
how they influence treatment decisions
Review NCCN and ASCO practice guidelines for MM
Understand glaucoma progression and patient demographics
Discuss the treatment algorithm of glaucoma
Discuss new technologies in treating glaucoma such at EX-PRESS®
Discuss the cost savings of new technologies when compared to current treatments
Review the updated practice guidelines from the American Association for the Study of Liver
Diseases (AASLD)
Describe the four main genotypes found in the US
Discuss screening measures to take to improve diagnosis
Describe treatment strategies for HCV
Discuss patient education for both avoiding HCV and to prevent spreading of HCV
Identify payers' top utilization management interventions and those they wish to implement in the
future
Describe steps oncologists are taking to manage their business in light of ASP reimbursement
trends
Quantify the major financial barriers faced by patients
Review the safety and efficacy of currently available chemotherapeutic treatments and targeted biologic therapies for advanced NSCLC
Examine ASCO and NCCN's latest guidelines on the treatment of advanced NSCLC
Discuss how treatments for NSCLC can be individualized, based on tumor histology, molecular markers, clinical factors, and patient characteristics
Analyze treatment regimens available for maintenance therapy and their role in advanced NSCLC
Identify patients with advanced NSCLC who are most likely to benefit from maintenance therapy